Scholarlink

<p>Simple lymphatic drainage (SLD) is a self-administered technique for managing lymphedema; however, its efficacy in preventing lower limb lymphedema (LLE) following pelvic lymphadenectomy remains unclear. This prospective study evaluated the preventive effects of SLD at a single institution. A total of 224 patients were enrolled who underwent gynecological cancer surgery with pelvic lymphadenectomy between April 2011 and May 2012. After excluding patients with deep vein thrombosis, age ≥ 80&#xa0;years, refusal to participate, and those with uncertain malignancy, 190 patients remained. A subset of 87 patients without adjuvant therapy was divided into two groups based on their preference: 24 in the SLD group and 63 in the control group. SLD group patients performed daily SLD for one year, and a 5-year follow-up was conducted. No significant differences were observed between groups in the change ratio of the lower limb circumference and the impedance method for the extracellular water: total body water ratio. The 5-year cumulative incidence of lymphedema (ISL stage I or more) was 37.5% in the SLD group and 23.5% in the control group, with no significant difference between the two groups. SLD does not contribute to the prevention of LLE following gynecological cancer surgery with pelvic lymphadenectomy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A prospective assessment of simple lymphatic drainage to prevent lower limb lymphedema in gynecological malignancies

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月28日

查看全文
  • Kuniko Utsugi,
  • Naoki Ishizuka,
  • Yukio Seki,
  • Hidetaka Nomura,
  • Atsushi Fusegi,
  • Hiroyuki Kanao

摘要

Simple lymphatic drainage (SLD) is a self-administered technique for managing lymphedema; however, its efficacy in preventing lower limb lymphedema (LLE) following pelvic lymphadenectomy remains unclear. This prospective study evaluated the preventive effects of SLD at a single institution. A total of 224 patients were enrolled who underwent gynecological cancer surgery with pelvic lymphadenectomy between April 2011 and May 2012. After excluding patients with deep vein thrombosis, age ≥ 80 years, refusal to participate, and those with uncertain malignancy, 190 patients remained. A subset of 87 patients without adjuvant therapy was divided into two groups based on their preference: 24 in the SLD group and 63 in the control group. SLD group patients performed daily SLD for one year, and a 5-year follow-up was conducted. No significant differences were observed between groups in the change ratio of the lower limb circumference and the impedance method for the extracellular water: total body water ratio. The 5-year cumulative incidence of lymphedema (ISL stage I or more) was 37.5% in the SLD group and 23.5% in the control group, with no significant difference between the two groups. SLD does not contribute to the prevention of LLE following gynecological cancer surgery with pelvic lymphadenectomy.